Dec 18, 2020
CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, on Thursday announced that it will be holding a conference call to discuss its recently approved Investigational New Drug (“IND”) application involving its lead product candidate Berubicin for the treatment of Glioblastoma Multiforme (“GBM”). The company also intends to discuss its planned Phase 2 Berubicin clinical trial on the call slated for Friday, December 18, 2020 at 8:30 AM ET. Interested parties may access the call by dialing (800) 226-2188 (domestic) or (602) 563-8462 (international) and using the conference ID: 6455799. After the conclusion of the call, a replay will be available through December 25, 2020. To access the replay, dial (855) 859-2056 (domestic) or (404) 537-3406 (international) and use the replay conference ID: 6455799.
To view the full press release, visit https://ibn.fm/hDXm6
About CNS Pharmaceuticals Inc.
CNS Pharmaceuticals is developing novel treatments for primary and metastatic cancers of the brain and central nervous system. Its lead drug candidate, Berubicin, is proposed for the treatment of glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. CNS holds a worldwide exclusive license to the Berubicin chemical compound and has acquired all data and know-how from Reata Pharmaceuticals Inc. related to a completed Phase 1 clinical trial with Berubicin in malignant brain tumors, which Reata conducted in 2006. In this trial, 44% of patients experienced a statistically significant improvement in clinical benefit. This 44% disease control rate was based on 11 patients (out of 25 evaluable patients) with stable disease, plus responders. One patient experienced a durable complete response and remains cancer-free as of February 20, 2020. These Phase 1 results represent a limited patient sample size and, while promising, are not a guarantee that similar results will be achieved in subsequent trials. By the end of 2020, CNS expects to commence a Phase 2 clinical trial of Berubicin for the treatment of GBM in the United States, while a sub-licensee partner undertakes a Phase 2 trial in adults and a first-ever Phase 1 trial in pediatric GBM patients in Poland. The company’s second drug candidate, WP1244, is a novel DNA binding agent that has shown in preclinical studies that it is 500 times more potent than the chemotherapeutic agent daunorubicin in inhibiting tumor cell proliferation. For more information about the company, please visit www.CNSPharma.com.
NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP
About BioMedWire
BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]
BioMedWire is part of the InvestorBrandNetwork
You'll have seen the coverage of Céline Dion's return from illness and her Paris residency. But here's a different angle: the audio technology keeping her stage quiet, and the artificial intelligence isolating her voice from the noise of a 30,000-seat stadium.
Read moreThe full Moon put on a stunning display over the skies of UK on Saturday night and here are some of your photographs.
Read moreAfter decades of investigating a mysterious formation high in the mountains, researchers have uncovered clues that point to the final resting place of Noah's Ark.
Read moreUS contract chipmaker GlobalFoundries sees robust demand for Chinese optical modules amid the data centre construction boom, as the firm expands its presence in China to better serve its domestic clients. Shankaran Janardhanan, senior vice-president of the firm’s photonics and radio frequency division, told the South China Morning Post in an interview that demand in the optical networking module segment was “strong”. The surging appetite for Chinese optical modules – used to transmit data in...
Read moreThe gap between technology and policymaking has gotten wider than ever with artificial intelligence, leaving a global policy vacuum as A.I. models rapidly advance.
Read moreWhatsApp is reportedly testing a redesigned Android bottom navigation bar that resembles its iPhone counterpart. Spotted in beta version 2.26.38.10, the bar features rounded edges and a floating design, according to reports.
Read moreLandmark legislation requiring large employers to cover infertility treatments went into effect at the beginning of the year. It's changed lives and boosted clinic caseloads – and left those who don't qualify scrambling to afford care.
Read moreThe pawpaw fruit tastes of banana, mango and pineapple and was once abundant across parts of North America, but it can still be found growing wild and in some orchards.
Read moreA new website dedicated to celebrating and promoting World Tourism Day has launched, bringing together a global events directory, stories from across the travel industry and opportunities for people and organisations to get involved.
Read moreTwo critical vulnerabilities in Citrix NetScaler ADC and NetScaler Gateway that allow remote code execution have been exploited in the wild, Citrix confirmed on September 27. It released fixes for both, along with six other flaws. One of the two affects every deployment on an affected version, including those in the default configuration. The bulletin came a day after security firm watchTowr
Read moreArtificial intelligence and digital platforms are increasingly steering the Indian tourism sector, driving more personalised and seamless travel experiences alongside record domestic and international visitor traffic.
Read moreTravel inspiration today is increasingly digital, with social media and artificial intelligence becoming important parts of how Indians discover and plan their journeys. A recent survey by zingbus, based on 2,371 respondents, reveals how short-form content, AI-powered planning and trusted travel information are influencing travel decisions. The findings come ahead of World Tourism Day on September 27, whose 2026 theme, “Digital Agenda and Artificial Intelligence to Redesign Tourism,” reflects the growing role of technology in shaping the future of travel.
Read moreYOUR NEWS, OUR NETWORK.
Do you have Great News you want to tell the world?
Be it updates about your business or your community, you can make sure that it’s heard by submitting your story to our network reaching hundreds of news sites across 6 verticals.
